Loading stock data…
Loading stock data…
US$36.27
Get one email when COLL crosses your level. Checked every 15 minutes during market hours.
▼ -0.45 (-1.23%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
55.4
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
0.43
Bearish momentumMACD below its signal line (0.47).
50-day average
34.78
Price aboveShort-term trend reference.
200-day average
39.22
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and neuropsychiatric conditions. The company's primary portfolio includes Jornay PM, a central nervous system stimulant for attention deficit hyperactivity disorder; Belbuca, a buccal film containing buprenorphine for chronic pain; and Xtampza ER, an abuse-deterrent extended-release oral formulation of oxycodone. Collegium also offers Nucynta products in exten…
www.collegiumpharma.com3 strong buy · 7 buy · 2 hold · 0 sell · 0 strong sell (12 analysts, 2026-07-01)
3 strong buy · 7 buy · 2 hold · 0 sell · 0 strong sell (12 analysts, 2026-06-01)
3 strong buy · 7 buy · 2 hold · 0 sell · 0 strong sell (12 analysts, 2026-05-01)
3 strong buy · 7 buy · 2 hold · 0 sell · 0 strong sell (12 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-06-08 | 0.33 | 0.49 | ✓ Beat |
| 2026-05-07 | 1.52 | 1.76 | ✓ Beat |
| 2026-02-26 | 2.14 | 2.04 | ✗ Miss |
| 2025-11-06 | 1.86 | 2.25 | ✓ Beat |
| 2025-09-17 | 2.01 | 1.97 | ✗ Miss |
| 2025-08-07 | 1.85 | 1.68 | ✗ Miss |
| 2025-05-08 | 1.45 | 1.49 | ✓ Beat |
Companies in the same industry, via Finnhub